Compare Lucid Group Inc (LCID) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Lucid Group Inc trades at $3.79 (market cap $1.51B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 38.9× Lucid Group Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| LCID | TAK | |
|---|---|---|
Market Cap | $1.51B | $58.74B |
Volume | 12,333,745 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.92 | $19.05 |
52-Week Low | $3.79 | $13.23 |
Typical Hold Time | 45 Days | 1 Days |
Enterprise Value | $4.40B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.82, down 1.8% on the day, with a bearish technical signal and weak fundamentals. The company reported a net loss of $2.70 billion in 2025, with negative gross and net income margins, and has missed earnings expectations for three consecutive quarters. Recent news highlights cost-saving initiatives and autonomous vehicle partnerships, but also delays in the Cosmos SUV launch and concerns over cash burn.
The outlook remains challenging due to persistent losses and high cash burn, though analyst consensus suggests potential upside with a $7.60 price target. Key risks include execution delays, competitive pressures, and the need for additional financing. Investor sentiment is cautious, with most analysts rating the stock Hold.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
